Physician profile
Mark I Debruin
NPI 1154327518
$9,753.48
in general payments reported to CMS, 2019-2025
34 companies · $1,578 in 2025
The $1,578 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $1,093 · 2021: $1,295 · 2022: $1,543 · 2023: $1,544 · 2024: $1,937 · 2025: $1,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,039 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,039.47 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,734.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $1,618.28 | 2021-2025 | |
| Amgen INC. | $1,079.64 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $931.27 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $740.78 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $716.42 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $581.01 | 2019-2025 | Ubrelvy |
| Exact Sciences Corporation | $397.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $321.61 | 2019-2024 | Belsomra, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.71 | 2019-2025 | Jardiance, Ofev |
| Pfizer INC. | $212.34 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $156.11 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $145.66 | 2022-2023 | Seglentis |
| Novartis Pharmaceuticals Corporation | $85.41 | 2022-2024 | |
| Eisai INC. | $84.68 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $76.93 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $73.02 | 2020-2021 | |
| Sanofi Pasteur INC. | $54.33 | 2024-2025 | |
| Corium, LLC | $46.71 | 2022 | |
| Janssen Pharmaceuticals, INC | $44.93 | 2022 | |
| Almatica Pharma LLC | $43.27 | 2024 | Loreev Xr |
| Alnylam Pharmaceuticals INC. | $40.31 | 2023-2024 | Onpattro |
| Biohaven Pharmaceutical Holding Company LTD. | $36.00 | 2022 | |
| Allergan, INC. | $31.08 | 2019-2020 | |
| Intra-Sana Laboratories | $28.00 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Dexcom, INC. | $26.93 | 2023 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $24.28 | 2025 | General - Pain Management |
| Merz North America, INC. | $23.42 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.07 | 2022 | |
| Organogenesis INC. | $20.20 | 2024 | Cygnus Dual |
| Phathom Pharmaceuticals, INC. | $19.03 | 2025 | Voquezna |
| Shire North American Group INC | $18.82 | 2019 | |
| Mannkind Corporation | $14.01 | 2025 | |
| Idorsia Pharmaceuticals US INC | $12.92 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Debruin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.